DE60316411T2 - Thiazolderivate als npy-rezeptorantagonisten - Google Patents

Thiazolderivate als npy-rezeptorantagonisten Download PDF

Info

Publication number
DE60316411T2
DE60316411T2 DE60316411T DE60316411T DE60316411T2 DE 60316411 T2 DE60316411 T2 DE 60316411T2 DE 60316411 T DE60316411 T DE 60316411T DE 60316411 T DE60316411 T DE 60316411T DE 60316411 T2 DE60316411 T2 DE 60316411T2
Authority
DE
Germany
Prior art keywords
thiazol
ylamino
methyl
benzoyl
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60316411T
Other languages
German (de)
English (en)
Other versions
DE60316411D1 (de
Inventor
Patrizio Mattei
Werner Neidhart
Matthias Heinrich Nettekoven
Philippe Pflieger
Sven Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE60316411D1 publication Critical patent/DE60316411D1/de
Application granted granted Critical
Publication of DE60316411T2 publication Critical patent/DE60316411T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/42Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60316411T 2002-02-28 2003-02-19 Thiazolderivate als npy-rezeptorantagonisten Expired - Fee Related DE60316411T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02004296 2002-02-28
EP02004296 2002-02-28
PCT/EP2003/001667 WO2003072577A1 (en) 2002-02-28 2003-02-19 Thiazole derivatives as npy receptor antagonists

Publications (2)

Publication Number Publication Date
DE60316411D1 DE60316411D1 (de) 2007-10-31
DE60316411T2 true DE60316411T2 (de) 2008-06-12

Family

ID=27763338

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60316411T Expired - Fee Related DE60316411T2 (de) 2002-02-28 2003-02-19 Thiazolderivate als npy-rezeptorantagonisten

Country Status (21)

Country Link
US (1) US6686381B2 (enExample)
EP (1) EP1480976B1 (enExample)
JP (1) JP2005526732A (enExample)
KR (1) KR100611854B1 (enExample)
CN (1) CN100363362C (enExample)
AR (1) AR038704A1 (enExample)
AT (1) ATE373654T1 (enExample)
AU (1) AU2003210305B2 (enExample)
BR (1) BR0308108A (enExample)
CA (1) CA2475299A1 (enExample)
DE (1) DE60316411T2 (enExample)
ES (1) ES2292992T3 (enExample)
GT (1) GT200300045A (enExample)
MX (1) MXPA04008379A (enExample)
PA (1) PA8567301A1 (enExample)
PE (1) PE20030930A1 (enExample)
PL (1) PL372463A1 (enExample)
RU (1) RU2004129285A (enExample)
TW (1) TW200403995A (enExample)
UY (1) UY27689A1 (enExample)
WO (1) WO2003072577A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
MXPA06001570A (es) * 2003-08-12 2006-05-15 Hoffmann La Roche Antagonistas del receptor de neuropeptido y (npy) 2-amino-5-benzoiltiazol.
EP1656374B1 (en) 2003-08-12 2009-03-11 F. Hoffmann-La Roche Ag Thiazole derivatives as npy antagonists
ES2298840T3 (es) 2003-12-08 2008-05-16 F. Hoffmann-La Roche Ag Derivados de tiazol.
MXPA06012130A (es) * 2004-04-20 2007-01-31 Transtech Pharma Inc Derivados de tiazol y pirimidina substituidos como moduladores del receptor de melanocortina.
FR2884516B1 (fr) * 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
EP1981884B1 (en) * 2006-01-18 2012-06-13 Amgen, Inc Thiazole compounds as protein kinase b (pkb) inhibitors
WO2010098298A1 (ja) * 2009-02-27 2010-09-02 塩野義製薬株式会社 栄養素の消化吸収抑制作用を有する化合物とシクロヘキサンカルボキサミド誘導体を組み合わせてなる医薬組成物
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
BR112020015581A2 (pt) 2018-01-31 2021-02-02 Deciphera Pharmaceuticals, Llc terapia de combinação para o tratamento de tumores estromais gastrointestinais
EP3746060A1 (en) 2018-01-31 2020-12-09 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of mastocytosis
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
SMT202300467T1 (it) 2019-12-30 2024-01-10 Deciphera Pharmaceuticals Llc Formulazioni di inibitori di chinasi amorfi e loro procedimenti d’uso
CN118948773A (zh) 2019-12-30 2024-11-15 德西费拉制药有限责任公司 1-(4溴-5-(1乙基-7-(甲氨基)-2侧氧基-1,2-二氢-1,6-萘啶-3基)-2氟苯基)-3-苯基脲的组合物
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
AUPN163795A0 (en) 1995-03-10 1995-04-06 DIPNALL, David A device for extracting energy from moving water particles
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
DE19824175A1 (de) * 1998-05-29 1999-12-02 Novartis Ag Amino-azol-Verbindungen
AU761351B2 (en) 1998-08-14 2003-06-05 Cheplapharm Arzneimittel Gmbh Pharmaceutical compositions containing lipase inhibitors
DE69916288T2 (de) 1998-08-14 2005-03-24 F. Hoffmann-La Roche Ag Lipasehemmer und chitosan enthaltende arzneimittel
US20010039275A1 (en) * 2000-02-04 2001-11-08 Bowler Andrew Neil Use of 2,4-diaminothiazole derivatives
AU2001246494A1 (en) * 2000-03-03 2001-09-12 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
EP1417188A1 (en) * 2001-08-03 2004-05-12 Novo Nordisk A/S Novel 2,4-diaminothiazole derivatives

Also Published As

Publication number Publication date
AU2003210305A1 (en) 2003-09-09
CN1639158A (zh) 2005-07-13
PA8567301A1 (es) 2004-02-07
CA2475299A1 (en) 2003-09-04
DE60316411D1 (de) 2007-10-31
KR100611854B1 (ko) 2006-08-11
WO2003072577A1 (en) 2003-09-04
PL372463A1 (en) 2005-07-25
JP2005526732A (ja) 2005-09-08
BR0308108A (pt) 2004-12-07
MXPA04008379A (es) 2004-11-26
CN100363362C (zh) 2008-01-23
TW200403995A (en) 2004-03-16
GT200300045A (es) 2003-09-23
ATE373654T1 (de) 2007-10-15
AR038704A1 (es) 2005-01-26
ES2292992T3 (es) 2008-03-16
AU2003210305B2 (en) 2006-07-06
PE20030930A1 (es) 2003-11-08
US20030225141A1 (en) 2003-12-04
EP1480976B1 (en) 2007-09-19
RU2004129285A (ru) 2005-10-27
UY27689A1 (es) 2003-08-29
US6686381B2 (en) 2004-02-03
EP1480976A1 (en) 2004-12-01
KR20040094735A (ko) 2004-11-10

Similar Documents

Publication Publication Date Title
DE60316411T2 (de) Thiazolderivate als npy-rezeptorantagonisten
EP2468717B1 (en) Heterocyclic Amide Compounds Useful as Kinase Inhibitors
KR101504787B1 (ko) 아졸카복사마이드 화합물 또는 그 염
JP2009544620A (ja) 自己免疫疾患及び炎症のためのプロリン尿素ccr1アンタゴニスト
CA2380866A1 (en) Selective npy (y5) antagonists
AU2003253364B2 (en) Thiazole derivatives
JP2003524574A (ja) 2,5−及び3,5−二置換アニリン誘導体、その調製及び使用
DE602004010529T2 (de) 2-amino-5-benzoylthiazol npy-antagonisten
KR20080003380A (ko) 우레아 유도체들, 그 제조방법 및 그 이용
JP5944483B2 (ja) アダマンチル基を有するスルファミド誘導体及びこれの薬剤学的に許容可能な塩
RU2321586C2 (ru) Производные тиазола в качестве антагонистов npy
DE69010772T2 (de) 1,2,4-Triazolderivate, ihre Herstellung und ihre Verwendung in der Behandlung von Bluthochdruck oder von Atemwegserkrankungen.
WO2009058919A1 (en) Ccr5 antagonists as therapeutic agents

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee